Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

• Published in: The world journal of biological psychiatry Vol. 22; no. 8; pp. 561 - 628
• Main Authors: Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M. L., de Leon, J., Greiner, C., Howes, O., Kim, E., Lanzenberger, R., Meyer, J. H., Moessner, R., Mulder, H., Müller, D. J., Reis, M., Riederer, P., Ruhe, H. G., Spigset, O., Spina, E., Stegman, B., Steimer, W., Stingl, J., Suzen, S., Uchida, H., Unterecker, S., Vandenberghe, F., Hiemke, C.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 2021
• Subjects: Antidepressants; brain imaging; Medicin och hälsovetenskap; pharmacogenetics; precision medicine; therapeutic drug monitoring; brain imaging; precision medicine; Antidepressants; pharmacogenetics; therapeutic drug monitoring
• ISSN: 1562-2975; 1814-1412; 1814-1412
• DOI: 10.1080/15622975.2021.1878427

Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient. Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug. Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.